Mounjaro vs Ozempic in the Philippines

Mounjaro is Eli Lilly’s tirzepatide. Ozempic is Novo Nordisk’s semaglutide. Both are once-weekly subcutaneous pens, both are registered for type 2 diabetes and prescribed off-label for weight loss, and both are prescription-only in the Philippines. Beyond that they are not the same kind of drug: tirzepatide activates two receptors and semaglutide activates one.

On efficacy the answer is not ambiguous. In SURMOUNT-5, the only head to head trial, tirzepatide produced 20.2 percent mean weight loss against 13.7 percent for semaglutide over 72 weeks. On price the answer is also not ambiguous, in the other direction: at Watsons Philippines the top Mounjaro strength costs more than three times the top Ozempic pen.

The interesting answer sits between those two, and it is the reason this page exists. Divide peso cost by kilograms lost and the ranking rearranges. Mounjaro at 5mg is among the most efficient options on the Philippine shelf. Mounjaro at 15mg is among the least efficient, because the extra strengths cost far more per pen than they add in weight loss. Ozempic 1mg, the strength Philippine pharmacies actually stock, sits between them and carries a trial number most comparison pages quietly substitute for a better one.

Every peso figure was read from the retailer’s own live product page on 25 August 2026. Philippine pharmacy pricing changes without notice and varies by branch, so click through and confirm before acting on any number here.

Semaglutide is a GLP-1 receptor agonist. GLP-1 is an incretin hormone the gut releases after eating, and a drug that mimics it slows gastric emptying, amplifies glucose-dependent insulin release and pushes on the satiety signal. That is one lever, pulled hard.

Tirzepatide pulls two. It is a dual agonist at both the GLP-1 receptor and the GIP receptor, GIP being the other major incretin. The clinical consequence is what the trials keep showing: for a given tolerability profile, adding the GIP arm buys more weight loss than the GLP-1 arm alone. It is not a stronger version of the same drug. It is a second mechanism running alongside the first.

The side effect profiles look similar on paper and for the same reason. Both drugs slow gastric emptying and both push on satiety signalling, so both produce nausea, vomiting and constipation concentrated in the weeks when the dose is being escalated rather than spread evenly across treatment. That is why both come with a long titration schedule instead of a starting dose you stay on, and why the starting strengths, tirzepatide 2.5mg and semaglutide 0.25mg, are explicitly not maintenance doses. A prescriber moving somebody up a strength every four weeks is following the label, not being cautious.

That difference matters practically in two ways. Dose numbers do not translate between them, so 5mg of tirzepatide is not comparable to 5mg of anything Novo Nordisk makes, and anyone converting between the two on a spreadsheet is doing something meaningless. And because the mechanisms overlap only partly, response to one does not fully predict response to the other, which is why switching is a clinical conversation rather than an arithmetic one.

Efficacy figures for these drugs get quoted without their durations constantly, which makes them useless. Every number below carries the trial, the dose and the length of time it took.

SURMOUNT-1 randomised 2,539 adults across nine countries and reported the figures above on the efficacy estimand, which measures effect prior to discontinuation. On the treatment-regimen estimand, which counts everyone regardless of whether they stopped, the same doses returned 15.0, 19.5 and 20.9 percent. STEP 1 randomised 1,961 adults over 68 weeks and reported 14.9 percent against 2.4 percent on placebo, with 50.5 percent of the treated group losing at least 15 percent of body weight.

SURMOUNT-5 is the trial that settles the efficacy question because it is the only one that ran the two molecules against each other. It randomised 751 participants one to one across the United States and Puerto Rico for 72 weeks, at maximum tolerated doses of tirzepatide 10 or 15mg against semaglutide 1.7 or 2.4mg, with 92.8 percent of the semaglutide arm receiving at least one 2.4mg dose. Tirzepatide won on both percentage and absolute kilograms.

Everything in this table was read from the retailer’s own product page on 25 August 2026. Prices checked 25 August 2026. Confirm at the counter before acting on any figure here.

Two things in that table deserve attention. The first is that Mounjaro pricing is not linear: the 15mg pen costs 2.2 times the 5mg pen for three times the drug, but in absolute pesos the step from 7.5mg to 15mg adds ₱9,550 a month. The second is that Wegovy 2.4mg at ₱12,650 undercuts Mounjaro 5mg at ₱13,550, which matters once the next section divides these numbers by results.

Neither figure includes what it costs to get the prescription. An endocrinology consultation and baseline bloodwork sit on top of every number here, and they recur. Our GLP-1 price filing and the cost calculator handle the total rather than the shelf price.

Comparing pen prices tells you which is more expensive. It does not tell you which is better value, because the pens do not deliver the same result. The honest metric is peso cost per kilogram of body weight lost, and running it reverses the ranking you would guess from the price list.

The arithmetic below holds a maintenance dose at Watsons Philippines pricing for the full trial duration, treats one pen as one month, and uses 16.6 months for a 72-week trial and 15.6 months for a 68-week one. Real spending is lower in the first months because everyone titrates up from a starting dose, and almost nobody stays on for exactly the trial length. Read this as a ranking tool, not a budget.

The cheapest pen on the Philippine shelf is the least efficient of the four. The most expensive is the second least efficient. The two mid-priced options, Mounjaro 5mg and Wegovy 2.4mg, are within a hundred pesos per kilogram of each other and beat both ends by roughly a third.

That is not an argument for any of them. Somebody who needs to lose 24kg cannot get there on a 5mg Mounjaro dose no matter how efficient the arithmetic looks, and somebody who tolerates 5mg but not 15mg has had the decision made for them. Efficiency per kilogram is one input among several, and the others, tolerability, comorbidities, what your prescriber will actually write and what your pharmacy can actually supply, are not on this table.

Both products reach Philippine buyers through registered pharmacy channels with prescription gates that are actually enforced. On 25 August 2026, Watsons Philippines listed Mounjaro KwikPen at 2.5, 5, 7.5, 10 and 15mg and Ozempic at 0.25, 0.5 and 1mg, each flagged prescription required. Watsons asks for the prescription to be emailed with the order number for pharmacist validation. Southstar Drug listed the Mounjaro 5mg KwikPen and states plainly that a doctor’s prescription is required, uploaded and validated before the order is fulfilled.

Availability is the weaker half of that sentence. Every Mounjaro strength checked at Watsons was restricted to click and collect, meaning pay online and pick up in branch rather than have it delivered. The Southstar Mounjaro listing was marked available soon rather than in stock. On the Ozempic side, Manila Bulletin’s 13 June 2026 report is the clearest published account of the rationing: pharmacies limiting sales to two pens per dosage per month, pharmacists screening which customers to serve, patients travelling between branches, and one patient going a month without medication. Prices in that report had moved from around ₱6,200 to ₱6,300 up to the ₱7,650 and ₱8,734 still listed at Watsons in August.

There is a second-order effect worth naming, because it shows up in Philippine consultation rooms. Manila Bulletin’s reporting recorded patients switching toward tirzepatide specifically because Ozempic was unavailable, while also noting that tirzepatide is harder to source locally and that some patients were turning to third-party sellers to get it. That is a shortage in one product pushing demand into a second product that is itself thinly stocked, and the pressure lands on exactly the channel with the least accountability. A switch made because a pharmacy shelf was empty is a different decision from a switch made because a prescriber recommended it, and only one of those belongs in a treatment plan.

The practical consequence is the one this site keeps repeating. When a registered channel rations, an unregistered one fills the gap, and pens from marketplaces, classifieds and resellers are the documented counterfeit route in this region. If a quote sits far below the pharmacy figures above, that gap is the story rather than the bargain. The spotting guide is the counterfeit Ozempic filing.